SGLT2 inhibitor
SGLT2 inhibitors (also called gliflozins or flozins ) are a class of medications that inhibit sodium-glucose transport proteins in the nephron (the functional units of the kidney ), unlike SGLT1 inhibitors tha…
Read guide →Topic guide
sglt2 peptides
Articles and reference material connected to this topic, organised for clear reading.
Reading path
Guides about sglt2 peptides
SGLT2 Inhibitors: Uses, Types, and Side Effects Explained
Uses Originally, SGLT2 inhibitors were developed to help people living with type 2 diabetes manage their blood glucose (sugar) levels. Later clinical trial data showed these medicines were also helpful for imp…
Read guide →SGLT2 inhibitors for diabetes
Sodium glucose cotransporter 2 (SGLT2) inhibitors are a newer, second line of medical treatment for the management of blood sugar levels in people with type 2 diabetes. SGLT2 inhibitors may help a person bette…
Read guide →SGLT2 Inhibitors
SGLT2 inhibitors are a type of medication used to treat type 2 diabetes . They are also known as gliflozins. What are SGLT2 inhibitors? How do SGLT2 inhibitors work? Who can take SGLT2 inhibitors? Different ty…
Read guide →Sodium-glucose co-transporter-2 inhibitors
Skip to main content Skip to article View PDF Under a Creative Commons license Open access Highlights • SGLT2i reduce cardiovascular events, especially heart failure, and protect the kidney. • SGLT2i behave as…
Read guide →SGLT2 Inhibitors: What They Are, Uses & Side Effects
A note from Cleveland Clinic Managing Type 2 diabetes can be a challenge. It can be overwhelming to keep track of medications, check your blood sugar, watch what you eat and stay active. Some days may feel exh…
Read guide →SGLT2 Inhibitors and GLP-1 Receptor Agonists: Indications
The following are key points to remember from a review article about established and emerging indications for sodium-glucose luminal cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) recep…
Read guide →SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic ...
Review Pharmacotherapy SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application Jae Hyun Bae 1,2 Diabetes & Metabolism Journal 2025;49(3):386-402. DOI…
Read guide →total risk - benefit of SGLT2 inhibitors and GLP1 agonists
Take-home messages Sodium-glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) agonists should be included in the treatment of patients with diabetes mellitus (DM) and underlying com…
Read guide →Sodium–glucose cotransporter-2 inhibition and acidosis in ...
Abstract Objective To evaluate whether adverse event reports to the US Food and Drug Administration on incidents of ketoacidosis from use of sodium glucose cotransport inhibitors (SGLT2 inhibitors) provide ins…
Read guide →Efficacy and safety of SGLT2 inhibitors with and without ...
Summary Background SGLT2 inhibitors and GLP-1 receptor agonists both improve cardiovascular and kidney outcomes in patients with type 2 diabetes . We sought to evaluate whether the benefits of SGLT2 inhibitors…
Read guide →SGLT2 inhibitors
Is a preferred 2nd line agent in cardiovascular disease, especially heart failure, and renal disease as reduces mortality from cardiovascular events and renal disease progression independent of effects on glyc…
Read guide →